Related references
Note: Only part of the references are listed.Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis
Osamu Takahashi et al.
CLINICAL CANCER RESEARCH (2012)
Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non-Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy
Fei Yang et al.
CANCER RESEARCH (2011)
VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis
Scott R. Silva et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Autocrine VEGF Signaling Synergizes with EGFR in Tumor Cells to Promote Epithelial Cancer Development
Beate M. Lichtenberger et al.
CELL (2010)
Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1
Katrin Duevel et al.
MOLECULAR CELL (2010)
AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
Krishna M. Vasudevan et al.
CANCER CELL (2009)
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions
Martin L. Sos et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
The angiogenic switch in carcinogenesis
Vanessa Baeriswyl et al.
SEMINARS IN CANCER BIOLOGY (2009)
Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma
Roland Ullrich et al.
CLINICAL CANCER RESEARCH (2008)
Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1
Tae-Hee Lee et al.
PLOS MEDICINE (2007)
Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray
GG Chung et al.
CANCER (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime?
BC Fuchs et al.
SEMINARS IN CANCER BIOLOGY (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors
S Blencke et al.
CHEMISTRY & BIOLOGY (2004)
TSC2 regulates VEGF through mTOR-dependent and -independent pathways
JB Brugarolas et al.
CANCER CELL (2003)
Positron emission tomographic imaging of angiogenesis and vascular function
GR Laking et al.
BRITISH JOURNAL OF RADIOLOGY (2003)
Mechanisms of angiogenesis and arteriogenesis
P Carmeliet
NATURE MEDICINE (2000)
Share Paper
